SAB BIOTHERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
SAB BIOTHERAPEUTICS, INC. (SABS) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$48.73 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-03-09
- SAB BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$38.72M.
- SAB BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$16.55M.
- SAB BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2024-12-31 was -$11.39M.
- SAB BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2024-09-30 was -$10.35M.
- SAB BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$48.73M.
- SAB BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$34.11M.
- SAB BIOTHERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2020 was $20.12M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$38.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$55.28M derived: sum of 2 quarters · filed 2026-03-09 | -$48.73M 10-K · filed 2026-03-09 | |
| 2025-09-30 | -$16.55M 10-Q · filed 2025-11-14 | -$10.00M 10-Q · filed 2025-11-14 | ||
| 2024-12-31 | -$11.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$21.74M derived: sum of 2 quarters · filed 2026-03-09 | -$34.11M 10-K · filed 2026-03-09 | |
| 2024-09-30 | -$10.35M 10-Q · filed 2025-11-14 | -$22.71M 10-Q · filed 2025-11-14 | ||
| 2022-03-31 | $985.86K 10-Q · filed 2022-05-12 | |||
| 2021-03-31 | $1.41M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $20.12M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |